A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT05039736
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this clinical research study is to learn about the safety and effectiveness of cabozantinib and nivolumab in people with hepatocellular carcinoma (HCC).

Key Dates

Start date
Feb 24, 2023
Status verified
May 2023
Primary completion
May 3, 2023
Completion
May 3, 2023

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: cabozantinib
    cabozantinib by mouth every day for 6 weeks
  • Experimental: nivolumab
    nivolumab by vein every 4 weeks for up to 2 years

Primary Outcome Measure

To evaluate overall response rate [ Time Frame: through study completion, an average of 1 year ]

Related Studies